NCT00201695View on ClinicalTrials.gov

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

August 31, 2008

Conditions
Multiple Myeloma
Interventions
DRUG

Doxil®

40 mg/m2 IV day 1

DRUG

Vincristine

1.4 mg/m2 (maximum 2 mg) IV day 1

DRUG

Dexamethasone

40 mg PO days 1-4

DRUG

Arsenic Trioxide

0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00201695 - Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | Biotech Hunter | Biotech Hunter